TY - JOUR
T1 - An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
AU - Sobas, Marta
AU - Montesinos, Pau
AU - Boluda, Blanca
AU - Bernal, Teresa
AU - Vellenga, Edo
AU - Nomdedeu, Josep
AU - González-Campos, Jose
AU - Chillón, Maria
AU - Holowiecka, Aleksandra
AU - Esteve, Jordi
AU - Bergua, Juan
AU - González-Sanmiguel, José David
AU - Gil-Cortes, Cristina
AU - Tormo, Mar
AU - Salamero, Olga
AU - Manso, Felix
AU - Fernández, Isolda
AU - de la Serna, Javier
AU - Moreno, María José
AU - Pérez-Encinas, Manuel
AU - Krsnik, Isabel
AU - Ribera, Josep Maria
AU - Escoda, Lourdes
AU - Lowenberg, Bob
AU - Sanz, Miguel Angel
PY - 2019/3/21
Y1 - 2019/3/21
N2 - © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p =.02) and 5-years cumulative incidence of relapse (33% versus 10%, p =.006), irrespectively of the Sanz score (low-risk 47% versus 5%, p <.001; intermediate 23% versus 7%, p <.001; and high-risk 42% versus 21%, p =.007). In the multivariate analysis, CD56 + (p <.0001), higher relapse-risk score (p =.001), and male gender (p =.05) retained the independent predictive value. CD56+ APL also showed a greater risk of CNS relapse (6% versus 1%, p <.001) and lower 5-year OS (75% versus 83%, p =.003). The AIDA-based LPA2012 trial, with an intensified consolidation schedule for CD56+ APL, will elucidate whether an intensified consolidation schedule could mitigate the relapse rate in this setting.
AB - © 2018, © 2018 Informa UK Limited, trading as Taylor & Francis Group. Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL presented higher induction death rate (16% vs 8%, p =.02) and 5-years cumulative incidence of relapse (33% versus 10%, p =.006), irrespectively of the Sanz score (low-risk 47% versus 5%, p <.001; intermediate 23% versus 7%, p <.001; and high-risk 42% versus 21%, p =.007). In the multivariate analysis, CD56 + (p <.0001), higher relapse-risk score (p =.001), and male gender (p =.05) retained the independent predictive value. CD56+ APL also showed a greater risk of CNS relapse (6% versus 1%, p <.001) and lower 5-year OS (75% versus 83%, p =.003). The AIDA-based LPA2012 trial, with an intensified consolidation schedule for CD56+ APL, will elucidate whether an intensified consolidation schedule could mitigate the relapse rate in this setting.
KW - Acute promyelocytic leukemia
KW - ATRA
KW - CD56
KW - chemotherapy
KW - prognostic
KW - relapse
UR - http://www.mendeley.com/research/analysis-impact-cd56-expression-novo-acute-promyelocytic-leukemia-patients-treated-upfront-alltrans
U2 - 10.1080/10428194.2018.1516875
DO - 10.1080/10428194.2018.1516875
M3 - Article
C2 - 30322324
SN - 1042-8194
VL - 60
SP - 1030
EP - 1035
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
ER -